Washington is currently home to 1729 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
An Observational Study of Individuals With Isolated Dystonia
NCT07111663
Recruiting
This is an observational study in individuals with isolated (or primary) dystonia that involves more than one body region. The purpose of the study is to collect detailed information to help your physician and other researchers understand how dystonia impacts your and other patients' lives and how the disease changes over time. The study may also help researchers better understand the clinical scales that are commonly used to evaluate dystonia symptoms and how they affect various areas of life s... Read More
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
08/01/2025
Locations: Vima Site #023, Kirkland, Washington
Conditions: Isolated/Primary Dystonia That Affects More Than One Region of the Body
Register for Updates
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742
Recruiting
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/01/2025
Locations: Pacific Northwest Retina, Bellevue, Washington
Conditions: Wet Age Related Macular Degeneration, wAMD
Register for Updates
Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial
NCT06661902
Recruiting
This phase I/II trial examines if buffered lidocaine reduces the pain that patients may experience during prostate biopsy. Prostate biopsies are typically performed awake, in the office, with only local anesthetic. As a result, many patients note considerable pain during these procedures. Local anesthetics such as lidocaine are typically acidic, which is thought to cause pain and burning during infiltration (injection). As a result, buffered local anesthetic has become the standard of care (SOC)... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Prostate Cancer
Register for Updates
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192
Recruiting
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/01/2025
Locations: University Of Washington, Seattle, Washington
Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer
Register for Updates
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080
Recruiting
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/01/2025
Locations: Swedish Cancer Institute - Edmonds Campus, Edmonds, Washington
Conditions: Large B-Cell Lymphoma
Register for Updates
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239
Recruiting
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Kadlec Clinic Hematology and Oncology, Kennewick, Washington
Conditions: Metastatic Breast Cancer
Register for Updates
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
08/01/2025
Locations: Providence Regional Cancer System-Aberdeen, Aberdeen, Washington
Conditions: Breast Cancer
Register for Updates
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769
Recruiting
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
08/01/2025
Locations: Western Washington Medical Group, Everett, Washington
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)
NCT05846516
Recruiting
The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. The main research objectives are: * to evaluate if the KISIMA-02 treatment is safe and well-tolerated (first part) * to evaluate if the KISIMA-02 treatment has an impact on the time to observe a possible reappearance of the tumor (second part) Participants will receive: i) a therapeutic protein vaccine ATP150 or ATP 152 ii) a viral vector VSV-GP154 iii) an immune checkpoint inhi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Virginia Mason Medical Center, Seattle, Washington
Conditions: Pancreatic Ductal Adenocarcinoma
Register for Updates
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT05735080
Recruiting
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 in patients with recurrent advanced/metastatic cancer, including hormone receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer who progressed on a prior cyclin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Northwest Medical Specialties, PLLC, Tacoma, Washington
Conditions: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
Register for Updates
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
NCT05705401
Recruiting
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/01/2025
Locations: Swedish Cancer Institute-Edmonds, Edmonds, Washington
Conditions: HER2-positive Breast Cancer
Register for Updates
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642
Recruiting
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
08/01/2025
Locations: Western Washington Medical Group, Everett, Washington
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates